WCN26-7471 PROTECTIVE EFFECT OF PARP1 DEFICIENCY ON RENAL FIBROSIS INDUCED BY REPEATED LOW-DOSE CISPLATIN

Read full text Summarise with VIRAT
Authors: JIABIN YU, J. Kim
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Cisplatin is a widely used chemotherapeutic drug for solid tumors, but its clinical application is limited by cumulative nephrotoxicity that progresses to chronic kidney disease (CKD) with irreversible fibrosis. Poly (ADP-ribose) polymerase 1 (PARP1) is known to exacerbate acute kidney injury; however, its role in repeated cisplatin-induced nephropathy remains unclear. This study investigated the protective effects and underlying mechanisms of Parp1 deficiency against repeated low-dose cisplatin (RLDC)-induced renal fibrosis.

Fields of Study & Subjects

Chemotherapy-induced organ toxicity mitigation Acute Kidney Injury Research Chronic Kidney Disease and Diabetes

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104524–104524
Publication date
25 March 2026
Language
EN